177 related articles for article (PubMed ID: 7907248)
1. Conjugate formation by leukemic blasts from acute myeloid leukemia with cytotoxic lymphocytes.
Palucka AK; Porwit A; Reizenstein P
Leuk Lymphoma; 1993 Nov; 11(5-6):427-33. PubMed ID: 7907248
[TBL] [Abstract][Full Text] [Related]
2. Binding of leukaemic blasts to various subpopulations of lymphokine-activated killer cells.
Palucka AK; Porwit A; Reizenstein P
Scand J Immunol; 1993 Feb; 37(2):179-85. PubMed ID: 7679523
[TBL] [Abstract][Full Text] [Related]
3. Susceptibility of acute myelogenous leukemia blasts to lysis by lymphokine-activated killer (LAK) cells and its clinical relevance.
Archimbaud E; Thomas X; Campos L; Fiere D; Doré JF
Leuk Res; 1992; 16(6-7):673-80. PubMed ID: 1378919
[TBL] [Abstract][Full Text] [Related]
4. Effect of human interleukin 3 on the susceptibility of fresh leukemia cells to interleukin-2-induced lymphokine activated killing activity.
Cesano A; Lista P; Bellone G; Geuna M; Brizzi MF; Rossi PR; Pegoraro L; Oberholtzer E; Matera L
Leukemia; 1992 Jun; 6(6):567-73. PubMed ID: 1376379
[TBL] [Abstract][Full Text] [Related]
5. Adhesion molecules on MHC-nonrestricted lymphocytes: high density expression and role in oncolysis.
Savary CA; Lotzová E
Lymphokine Cytokine Res; 1992 Jun; 11(3):149-56. PubMed ID: 1391234
[TBL] [Abstract][Full Text] [Related]
6. A supportive role of neural cell adhesion molecule (NCAM) in adhesion between leukaemic blasts and cytotoxic lymphocytes.
Palucka AK; Porwit A; Reizenstein P
Scand J Immunol; 1992 Apr; 35(4):399-406. PubMed ID: 1373000
[TBL] [Abstract][Full Text] [Related]
7. Possible mechanism of selective killing of myeloid leukemic blast cells by lymphokine-activated killer cells.
Oblakowski P; Bello-Fernandez C; Reittie JE; Heslop HE; Galatowicz G; Veys P; Wilkes S; Prentice HG; Hazlehurst G; Hoffbrand AV
Blood; 1991 May; 77(9):1996-2001. PubMed ID: 1708296
[TBL] [Abstract][Full Text] [Related]
8. Target lysis by human LAK cells is critically dependent upon target binding properties, but LFA-1, LFA-3 and ICAM-1 are not the major adhesion ligands on targets.
Quillet-Mary A; Cavarec L; Kermarrec N; Marchiol-Fournigault C; Gil ML; Conjeaud H; Fradelizi D
Int J Cancer; 1991 Feb; 47(3):473-9. PubMed ID: 1704356
[TBL] [Abstract][Full Text] [Related]
9. Prolactin increases the susceptibility of primary leukemia cells to NK and LAK effectors.
Oberholtzer E; Contarini M; Veglia F; Cossarizza A; Franceschi C; Geuna M; Provinciali M; Di Stefano G; Sissom J; Brizzi MF; Pegoraro L; Matera L
Adv Neuroimmunol; 1996; 6(3):233-47. PubMed ID: 8968423
[TBL] [Abstract][Full Text] [Related]
10. Resistance of leukemic blasts to lymphokine activated killer (LAK)-mediated cytotoxicity is not related to their adhesion properties.
Palucka AK; Porwit A; Reizenstein P
Eur J Haematol; 1991 Aug; 47(2):123-7. PubMed ID: 1716215
[TBL] [Abstract][Full Text] [Related]
11. Selective targeting of human lymphokine-activated killer cells by CD3 monoclonal antibody against the interferon-inducible high-affinity Fc gamma RI receptor (CD64) on autologous acute myeloid leukemic blast cells.
Notter M; Ludwig WD; Bremer S; Thiel E
Blood; 1993 Nov; 82(10):3113-24. PubMed ID: 7693036
[TBL] [Abstract][Full Text] [Related]
12. Strength of binding between leukemic blasts and cytotoxic lymphocytes.
Palucka AK; Waniewski J; Porwit A
Cytometry; 1996 Apr; 23(4):330-6. PubMed ID: 8900476
[TBL] [Abstract][Full Text] [Related]
13. Defective lymphokine-activated killer cell generation and activity in acute leukemia patients with active disease.
Foa R; Fierro MT; Cesano A; Guarini A; Bonferroni M; Raspadori D; Miniero R; Lauria F; Gavosto F
Blood; 1991 Aug; 78(4):1041-6. PubMed ID: 1868239
[TBL] [Abstract][Full Text] [Related]
14. In vitro susceptibility of acute leukemia cells to the cytotoxic activity of allogeneic and autologous lymphokine activated killer (LAK) effectors: correlation with the rate and duration of complete remission and with survival.
Lauria F; Raspadori D; Rondelli D; Ventura MA; Foà R
Leukemia; 1994 May; 8(5):724-8. PubMed ID: 8182932
[TBL] [Abstract][Full Text] [Related]
15. Resistance of some leukemic blasts to lysis by lymphokine activated killer (LAK) cells.
Panayotides P; Porwit A; Sjögren AM; Wasserman J; Reizenstein P
Eur J Haematol; 1988 Apr; 40(4):362-7. PubMed ID: 3259192
[TBL] [Abstract][Full Text] [Related]
16. Adhesion molecule-mediated signals regulate major histocompatibility complex-unrestricted and CD3/T cell receptor-triggered cytotoxicity.
Galandrini R; Albi N; Zarcone D; Grossi CE; Velardi A
Eur J Immunol; 1992 Aug; 22(8):2047-53. PubMed ID: 1379184
[TBL] [Abstract][Full Text] [Related]
17. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
18. Expression of adhesion molecules on acute leukemic blast cells and sensitivity to normal LAK activity.
Raspadori D; Lauria F; Ventura MA; Rondelli D; Tura S
Ann Hematol; 1993 Nov; 67(5):213-6. PubMed ID: 7694662
[TBL] [Abstract][Full Text] [Related]
19. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
20. GM-CSF enhances IL-2-activated natural killer cell lysis of clonogenic AML cells by upregulating target cell expression of ICAM-1.
Bendall LJ; Kortlepel K; Gottlieb DJ
Leukemia; 1995 Apr; 9(4):677-84. PubMed ID: 7723403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
